Procalcitonin- A Biomarker for Severity of Preeclampsia
Authors/Creators
- 1. International Journal of Medical Science and Innovative Research (IJMSIR)
Description
Abstract
Introduction: Hypertensive disorders of pregnancy, affecting approximately 10% of pregnancies, include chronic hypertension, gestational hypertension, and preeclampsia. Preeclampsia poses significant risks, including maternal and fetal morbidity and mortality. Elevated levels of pro-inflammatory cytokines, such as procalcitonin (PCT), have been observed in preeclampsia, indicating its potential as a biomarker.
Aim: The study aimed to evaluate the levels of procalcitonin (PCT) in preeclamptic patients compared to normotensive pregnant women, to explore its potential as a biomarker for preeclampsia.
Methods: This prospective study included antenatal women between 30-34 weeks gestation, divided into two groups: Group A (preeclamptic) and Group B (normotensive). Clinical assessments, including blood pressure measurements, were conducted. Serum procalcitonin was measured using the VITROS B.R.A.H.M.S test. Statistical analysis compared mean PCT levels between groups and evaluated correlations with clinical parameters.
Results: Group A (preeclampsia) had significantly higher systolic (155.56±3.26 mmHg) and diastolic (94.76±3.02 mmHg) blood pressure compared to Group B (120.32±6.24 mmHg and 84.63±3.44 mmHg, respectively; p<0.0001). Mean procalcitonin levels were also significantly higher in Group A (0.55±0.26) versus Group B (0.04±0.02; p<0.0001). Positive correlations were found between PCT levels and systolic (r=0.39) and diastolic blood pressure (r=0.41) and corelation of procalcitonin with severity of preeclampsia.
Conclusion: Pregnant women with preeclampsia exhibit elevated procalcitonin levels compared to those with normal pregnancies, suggesting that PCT may reflect the heightened inflammatory response associated with preeclampsia. These findings indicate PCT's potential as a biomarker for early diagnosis and severity differentiation in preeclampsia.
Files
KOMAL.pdf
Files
(1.1 MB)
| Name | Size | Download all |
|---|---|---|
|
md5:544e7b29eb11c2e32c4c5f6b9a80d5b7
|
1.1 MB | Preview Download |
Additional details
Software
References
- 1. Acog Practice Bulletin. Clinical Management Guidelines for Obstetrician–Gynecologists. Replaces. Practice Bulletin 2020;135(6):237-260. 2. Burton GJ, Redman CW, Roberts JM, Moffett A. Pre-eclampsia: pathophysiology and clinical implications. The BMJ. 2019;366:1–15. 3. Agostinis C, Rami D, Zacchi P, Bossi F, Stampalija T, Mangogna A, et al. Pre-eclampsia affects procalcitonin production in placental tissue. American Journal of Reproductive Immunology. 2018;79(4):1 12. 4. Duckworth S, Griffin M, Seed PT, North R, Myers J, Mackillop L, et al. Diagnostic Biomarkers in Women with Suspected Preeclampsia in a Prospective Multicenter Study. Obstetrics and Gynecology. 2016;128(2):245–52. 5. Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: A systematic review and meta-analysis. Lancet Infect Dis 2013;13(5):426-435. 6. Kucukgoz Gulec U, Tuncay Ozgunen F, Baris Guzel A, Buyukkurt S, Seydaoglu G, Ferhat Urunsak I, et al. An analysis of C reactive protein, procalcitonin, and D dimer in pre eclamptic patients. Am J Reprod Immunol 2012;68:331 7. 7. Jannesari R, Kazemi E. Level of High Sensitive C-reactive Protein and Procalcitonin in Pregnant Women with Mild and Severe Preeclampsia. Adv Biomed Res 2017;6:140. 8. Fatimah N I, Wahyuni S, Arifuddin S. Procalcitonin Levels Differences in Preeclampsia and Non Preeclampsia. International Journal of Health Sciences 2021;5(2): 71-78. 9. Aydın SM, Tekeli Taşkömür A. Evaluation of Serum Procalcitonin, Neutrophil-lymphocyte Ratio and Platelet-lymphocyte Ratio in Pregnancies with Threatened Abortion. Actual Gyn. 2022;14:31-37. 10. Setiawan G W, Suparman E, Wgery F W. The relationship between procalcitonin level in severe preeclampsia and normotensive pregnancy. Teikyo Medical Journal (2022);45(2):5633-5641.